Non-Patent Literature 1: Nie, S. et al., J. Proteome Res. 13: 1873-1884, 2014

Non-Patent Literature 2: Koths, K. et al., J. Biol. Chem. 268: 14245-14249, 1993

Summary

[0006a]

In a first aspect, the present disclosure refers to a method for analyzing a biological sample obtained from a subject, comprising:

analyzing components contained in a biological sample by an assay using a first molecule selected from the group consisting of a molecule binding to a sugar chain bindable with BC2LCN, a molecule binding to SerpinA3, and a molecule binding to Gal3BP, and a second molecule that is BC2LCN.

[0006b]

In another aspect, the present disclosure refers to a kit for a sandwich assay, a kit for an immunochromatographic assay, a kit for lectin electrophoresis, a kit for mass spectrometry, a kit for lectin affinity chromatography, or a kit for μTAS, comprising:

a first molecule selected from the group consisting of BC2LCN, a molecule binding to SerpinA3, and a molecule binding to Gal3BP; and

a second molecule that is a molecule binding to a sugar chain bindable with BC2LCN,

wherein the kit is capable of being used to measure an amount of a glycoprotein in a biological sample of a subject, using the first molecule and the second molecule.

[0006c]

In yet another aspect, the present disclosure refers to a method for predicting whether or not a subject has a cancer, comprising carrying out the method as disclosed herein.

[0006d]

In a further aspect, the present disclosure refers to a method for detecting a specific component in a biological sample obtained from a subject,

wherein the specific component is a component selected from the group consisting of a component that can simultaneously bind to two BC2LCN's, SerpinA3 bindable with BC2LCN, and Gal3BP bindable with BC2LCN.

[0006e]

In another aspect, the present disclosure refers to a method comprising separating one or more components selected from the group consisting of a component that can simultaneously

bind to two BC2LCN's, SerpinA3, and Gal3BP from a biological sample obtained from a subject.

[0007]

The present disclosure relates to a cancer test method and a test kit for the same.

[0008]

According to the present disclosure, the following examples are provided.

(1) A method for analyzing a blood sample obtained from a subject, comprising:

analyzing a blood component contained in a blood sample by a sandwich assay or an immunochromatographic assay, using a first molecule selected from the group consisting of BC2LCN, an antibody binding to SerpinA3, and an antibody binding to Gal3BP, and a second molecule that is BC2LCN.

(2) The method as described in (1),

in which the first molecule is an antibody binding to SerpinA3.

(3) The method as described in (1),

in which the first molecule is an antibody binding to Gal3BP.

(4) The method as described in (1),

in which the first molecule is BC2LCN.

(5) The method as described in any one of (1) to (4),

in which the subject has a cancer or has a potential to have the cancer.

(6) The method as described in (5),

in which the subject has a pancreatic cancer or has a potential to have the pancreatic cancer.

(7) The method as described in (6),

in which the subject has a stage I or II pancreatic cancer or has a potential to have the stage I or II pancreatic cancer.

(8) A kit for a sandwich assay or an immunochromatographic assay, comprising a first molecule selected from the group consisting of BC2LCN, an antibody binding to SerpinA3, and an antibody binding to Gal3BP, and a second molecule that is BC2LCN,

in which the kit can be used to measure an amount of a glycoprotein in a blood sample of a subject, using the first molecule and the second molecule.

(9) The kit as described in (8),

in which the first molecule is an antibody binding to SerpinA3 and a protein portion of

the glycoprotein is SerpinA3.

(10) The kit as described in (8),

in which the first molecule is an antibody binding to Gal3BP and a protein portion of the glycoprotein is Gal3BP.

(11) The kit as described in (8), comprising:

a second molecule that is immobilized BC2LCN; and

a first labeled molecule selected from the group consisting of labeled BC2LCN, an antibody binding to labeled SerpinA3, and an antibody binding to labeled Gal3BP.

(12) The kit as described in any one of (8) to (11),

in which the kit is used for detecting a cancer.

(13) The kit as described in (12),

in which the cancer is a cancer selected from the group consisting of a pancreatic cancer and a colorectal cancer.

(14) The kit as described in (13),

in which the cancer is a stage I or II pancreatic cancer.

(15) A method for predicting whether or not a subject is a cancer, comprising carrying out the method as described in (1) to (7).

(16) A method for analyzing a blood sample obtained from a subject, comprising:

analyzing the presence or absence or the concentration of a blood component in a blood sample,

in which the blood component is a component selected from the group consisting of a component that can simultaneously bind to two BC2LCN's, SerpinA3 bindable with BC2LCN, and Gal3BP bindable with BC2LCN.

According to the present disclosure, the following examples may also be provided.

(1A) A method for analyzing a biological sample obtained from a subject, comprising:

analyzing components contained in a biological sample by an assay using a first molecule selected from the group consisting of a molecule binding to a sugar chain bindable with BC2LCN, a molecule binding to SerpinA3, and a molecule binding to Gal3BP, and a second molecule that is BC2LCN.

(2A) The method as described in (1A),

in which the first molecule is an antibody binding to SerpinA3.

(3A) The method as described in (1A),

in which the first molecule is an antibody binding to Gal3BP.